Key Takeaways:
- Silence Therapeutics shares surged 107% in six months through July 16, 2026
- Investors are focused on pivotal divesiran data expected later in 2026
- The RNAi biotech competes with Alnylam and Arrowhead in a growing field
Back
Silence Therapeutics surges 107% as divesiran data looms in 2026
Silence Therapeutics PLC shares surged 107% in six months as investors focused on key divesiran data expected in 2026 and progress across the company's RNAi pipeline.
Silence Therapeutics PLC shares more than doubled in the past six months, surging 107%, as investors focused on a pivotal data readout for lead candidate divesiran and advancing RNAi pipeline programs.
"Silence Therapeutics is advancing multiple siRNA programs targeting indications with high unmet need," the company said in its most recent pipeline update. The London-based biotech has positioned divesiran, an siRNA therapeutic targeting the complement pathway, as its most advanced wholly owned candidate.
The 107% surge through July 16 outpaced the broader biotech sector by a wide margin. Silence Therapeutics' rally reflects investor conviction in its mRNAi GOLD platform, which aims to improve siRNA stability and delivery — two challenges that have historically limited the field. Alnylam Pharmaceuticals Inc., the RNAi pioneer with three approved drugs and a market capitalization above $30 billion, demonstrated the commercial viability of the modality.
For Silence Therapeutics, the divesiran readout represents a binary catalyst that will determine whether the company can compete with better-capitalized rivals including Alnylam and Arrowhead Pharmaceuticals Inc. A positive result could open a path to regulatory filing and partnership interest from larger pharmaceutical companies. A negative outcome risks reversing the gains accumulated over the past six months.
The company's pipeline includes additional siRNA programs in preclinical and early clinical development, though divesiran remains the primary value driver. Silence Therapeutics is developing the drug for complement-mediated diseases, an area where Alnylam's cemdisiran has also shown activity. The competitive landscape in RNAi therapeutics has intensified since Novo Nordisk A/S acquired Dicerna Pharmaceuticals for $3.3 billion in 2021, validating the platform approach and setting a valuation benchmark for RNAi-focused companies.
The RNAi Competitive Landscape
Silence Therapeutics' mRNAi GOLD platform is designed to produce siRNAs with enhanced stability and targeted delivery, aiming to overcome two of the field's historical challenges: efficient delivery to extrahepatic tissues and durable target silencing. Arrowhead Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc. are also advancing RNA-targeted programs, creating a competitive field of roughly a dozen publicly traded companies in the space.
Silence Therapeutics shares, which have more than doubled this year, now trade at a valuation that reflects expectations of a positive divesiran outcome. The binary nature of the setup means continued upside if data meet or exceed expectations, or a sharp correction if results disappoint. The company's cash runway and potential partnership interest from larger pharmaceutical companies seeking RNAi assets provide some downside protection. Alnylam's market cap and Novo Nordisk's $3.3 billion Dicerna acquisition offer reference points for what a validated RNAi platform could be worth.
This article is for informational purposes only and does not constitute investment advice.
